With the latest collaboration, the companies aim to speed-up the development of BioNTech’s BNT162 as a potential Covid-19 vaccine via the ‘Lightspeed program.’
BioNTech also formed a strategic development and commercialisation partnership with Shanghai Fosun Pharmaceutical to advance BNT162 for protection from Covid-19 in China. As part of the deal, the companies will co-develop the candidate in China and perform clinical trials by utilising Fosun’s clinical development, regulatory and commercial expertise in the country.
BioNTech’s Covid-19-focused project includes four vaccine candidates. Two of these candidates consist of a nucleoside modified mRNA, one includes a uridine containing mRNA and the fourth candidate has self-amplifying mRNA. The company has included a larger spike sequence in two of the vaccine candidates and the spike protein’s smaller optimised receptor binding domain (RBD) in the remaining two.
Rationale
Rationale
Rationale